Oppenheimer Lowers Teladoc Health (NYSE:TDOC) Price Target to $37.00

Teladoc Health (NYSE:TDOC – Get Rating) had its price target cut by analysts at Oppenheimer from $45.00 to $37.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s price objective indicates a potential upside of 41.33% from the company’s current price. Oppenheimer also issued estimates for Teladoc Health’s FY2025 earnings at ($0.82) EPS.

Several other equities analysts have also weighed in on TDOC. Cowen decreased their target price on shares of Teladoc Health to $30.00 in a report on Thursday, October 27th. Barclays decreased their price target on Teladoc Health from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Canaccord Genuity Group cut their price objective on Teladoc Health from $45.00 to $43.00 in a research report on Friday, October 28th. StockNews.com upgraded shares of Teladoc Health to a “sell” rating in a research report on Thursday, January 5th. Finally, Guggenheim raised shares of Teladoc Health from a “sell” rating to a “neutral” rating in a research report on Monday, October 24th. One analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $47.79.

Teladoc Health Stock Up 5.0 %

Shares of TDOC opened at $26.18 on Thursday. The stock has a 50 day moving average price of $26.45 and a 200 day moving average price of $30.30. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.99 and a current ratio of 3.13. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -0.43 and a beta of 0.98. Teladoc Health has a one year low of $21.60 and a one year high of $80.83.

Teladoc Health (NYSE:TDOC – Get Rating) last announced its quarterly earnings data on Wednesday, October 26th. The health services provider reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.14. The company had revenue of $611.40 million during the quarter, compared to analysts’ expectations of $609.45 million. Teladoc Health had a negative net margin of 424.40% and a negative return on equity of 2.47%. Equities research analysts forecast that Teladoc Health will post -1.4 earnings per share for the current fiscal year.

Insider Transactions at Teladoc Health

In related news, insider Arnnon Geshuri sold 2,398 shares of the company’s stock in a transaction on Monday, November 28th. The stock was sold at an average price of $27.35, for a total transaction of $65,585.30. Following the transaction, the insider now owns 74,317 shares of the company’s stock, valued at $2,032,569.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Teladoc Health news, SVP Daniel Trencher sold 1,000 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $26.80, for a total value of $26,800.00. Following the sale, the senior vice president now owns 21,408 shares of the company’s stock, valued at $573,734.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arnnon Geshuri sold 2,398 shares of Teladoc Health stock in a transaction on Monday, November 28th. The stock was sold at an average price of $27.35, for a total value of $65,585.30. Following the transaction, the insider now directly owns 74,317 shares of the company’s stock, valued at approximately $2,032,569.95. The disclosure for this sale can be found here. Insiders have sold a total of 3,925 shares of company stock worth $107,958 over the last ninety days. 1.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in shares of Teladoc Health by 879.2% in the second quarter. Renaissance Technologies LLC now owns 4,475,319 shares of the health services provider’s stock worth $148,625,000 after acquiring an additional 4,018,300 shares during the last quarter. State of Michigan Retirement System acquired a new stake in shares of Teladoc Health during the 2nd quarter worth about $123,089,000. Himension Capital Singapore PTE. LTD. boosted its stake in shares of Teladoc Health by 67.7% during the 2nd quarter. Himension Capital Singapore PTE. LTD. now owns 2,167,552 shares of the health services provider’s stock worth $71,984,000 after purchasing an additional 875,344 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Teladoc Health by 46.6% in the third quarter. Two Sigma Advisers LP now owns 1,661,711 shares of the health services provider’s stock valued at $42,124,000 after buying an additional 528,100 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Teladoc Health by 97.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 693,369 shares of the health services provider’s stock valued at $17,577,000 after buying an additional 341,471 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.